Wolfgang Miesbach on Landmark 5-Year Haemophilia B Gene Therapy Results
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared on LinkedIn:
”Visualizing 5-year outcomes of haemophilia B gene therapy. Following up on yesterday’s post about the 5-year HOPE-B results in the New England Journal of Medicine and Steve Pipe’s ASH presentation, here are three key slides that really bring the data to life:
Durable, therapeutic FIX levels at 5 years
Most participants maintained FIX levels in the mild or near-normal range, with >90% between 5–100 IU/dL. The remarkable consistency across the cohort demonstrates sustained gene expression.
Similar FIX expression regardless of pre-existing AAV5 neutralizing antibodies
The boxplots illustrate a pivotal finding: no substantial difference in endogenous FIX activity over time, even in those with pre-existing AAV5 antibodies. This is a game-changer for expanding eligibility in real-world practice – many patients previously thought “ineligible” can now benefit.
Stable FIX activity over the full 5-year follow-up
Mean FIX levels peaked early and then stabilized, remaining in the therapeutic range (mean FIX activity: 39 % and no supraphysiological levels) through Year 5.
- What else the full presentation reveal:
- Hepatic safety: Early ALT elevation managed successfully without loss of therapeutic response
- 94% freedom from FIX prophylaxis – transforming daily management into treatment-free living
- 85% reduction in annualized joint bleeding rate – from 2.34 to 0.35
- Zero FIX inhibitors | Zero thrombotic events
Deep gratitude to Steve Pipe, the HOPE-B investigators, CSL, and above all, the 54 participants whose courage and commitment made these landmark 5-year data possible.”
Stay updated with Hemostasis Today.
-
Dec 11, 2025, 16:18Caitlin Raymond’s Commentary on Artificial Intelligence in Transfusion Medicine is Out!
-
Dec 11, 2025, 15:20Giles Platford on Takeda’s 5 Year Deal with WFH for The Humanitarian Aid Program!
-
Dec 11, 2025, 15:05Kristof Vercruysse on ”First in Human” Presented at ASH25
-
Dec 11, 2025, 13:59Jeff Schaffnit Shares Sanofi’s Patient Advocacy Voices Series with Caroline Kruse
-
Dec 11, 2025, 12:50Harlan Krumholz on Half-Life of Evidence and The Need for Real-Time Trials
-
Dec 11, 2025, 12:34Riitta Lassila on LMWH Benefits in COVID19
-
Dec 11, 2025, 12:30A Neutrophil-Mesangial Cell Axis Promotes Glomerular Injury in Lupus Nephritis
-
Dec 11, 2025, 12:27Roula Farah: Discussing Rare Bleeding Disorders in Abu Dhabi
-
Dec 11, 2025, 12:21Amirali Ebrahimpour: Escherichia coli–Related DIC Case Report